Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Riedmann, K; Bassermann, F; Jost, PJ.
[Kinase inhibitors in oncology : What is new?]
Internist (Berl). 2019; 60(5):540-544 Doi: 10.1007/s00108-019-0577-8
Web of Science PubMed FullText FullText_MUG


Co-Autor*innen der Med Uni Graz
Jost Philipp

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Kinase inhibitors are now among the most important drugs in targeted therapy and are used in particular for the treatment of different tumor entities. Since many kinase inhibitors inhibit various tyrosine kinases efficiently but not specifically, they are often characterized by their versatile use in a wide variety of entities and diseases. The diverse use of this group of drugs, as well as the challenge of their side-effect profile, continues to make kinase inhibitors the subject of numerous clinical studies. The following article provides an overview of recent new approvals in the field of kinase inhibitors and shows their importance for oncological therapy.
Find related publications in this database (using NLM MeSH Indexing)
Antineoplastic Agents - therapeutic use
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - pathology
Humans -
Leukemia, Myeloid - drug therapy
Leukemia, Myeloid - pathology
Medical Oncology - trends
Molecular Targeted Therapy -
Neoplasms - drug therapy
Protein Kinase Inhibitors - adverse effects
Protein Kinase Inhibitors - therapeutic use
Protein-Tyrosine Kinases -

Find related publications in this database (Keywords)
Protein kinase inhibitors
adverse effects
Protein-tyrosine kinases
Molecular targeted therapy
Leukemia, myeloid
Carcinoma, non-small-cell lung
© Med Uni Graz Impressum